Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E Cortes

Showing results (381-390 of 584) with videos related to

Pageof 59
Sort By:
Blood|February 27, 2014
Long-term outcome with dasatinib after imatinib failure in chronic-phase chronic myeloid leukemia: follow-up of a phase 3 studyNeil P Shah, François Guilhot, Jorge E Cortes, et al.
Clinical Lymphoma, Myeloma & Leukemia|June 22, 2013
Subcutaneous omacetaxine mepesuccinate in patients with chronic-phase chronic myeloid leukemia previously treated with 2 or more tyrosine kinase inhibitors including imatinibJorge E Cortes, Franck E Nicolini, Meir Wetzler, et al.
Oncotarget|September 23, 2016
A phase I-II trial of fludarabine, bendamustine and rituximab (FBR) in previously treated patients with CLLNitin Jain, Kumudha Balakrishnan, Alessandra Ferrajoli, et al.
The Pediatric Infectious Disease Journal|December 25, 2010
Sustained decline in rotavirus detections in the United States following the introduction of rotavirus vaccine in 2006Jacqueline E Tate, Jeffry D Mutuc, Catherine A Panozzo, et al.
American Journal of Hematology|June 5, 2015
Long-term efficacy and safety of bosutinib in patients with advanced leukemia following resistance/intolerance to imatinib and other tyrosine kinase inhibitorsCarlo Gambacorti-Passerini, Hagop M Kantarjian, Dong-Wook Kim, et al.
Blood|December 19, 2013
Bosutinib safety and management of toxicity in leukemia patients with resistance or intolerance to imatinib and other tyrosine kinase inhibitorsHagop M Kantarjian, Jorge E Cortes, Dong-Wook Kim, et al.
Brain Sciences|November 27, 2024
The Development of a Brief but Comprehensive Therapeutic Assessment Protocol for the Screening and Support of Youth in the Community to Address the Youth Mental Health CrisisMargaret Danielle Weiss, Eleanor Castine Richards, Danta Bien-Aime, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 29, 2008
Phase I study of alternate-week administration of tipifarnib in patients with myelodysplastic syndromeRazelle Kurzrock, Hagop M Kantarjian, Michelle A Blascovich, et al.
The Pediatric Infectious Disease Journal|December 25, 2010
Uptake, impact, and effectiveness of rotavirus vaccination in the United States: review of the first 3 years of postlicensure dataJacqueline E Tate, Margaret M Cortese, Daniel C Payne, et al.
British Journal of Haematology|November 6, 2015
Factors influencing long-term efficacy and tolerability of bosutinib in chronic phase chronic myeloid leukaemia resistant or intolerant to imatinibTim H Brümmendorf, Jorge E Cortes, Hanna J Khoury, et al.
Pageof 59

Showing results (381-390 of 584) with videos related to

Sort By:
Pageof 59
Blood|February 27, 2014
Long-term outcome with dasatinib after imatinib failure in chronic-phase chronic myeloid leukemia: follow-up of a phase 3 studyNeil P Shah, François Guilhot, Jorge E Cortes, et al.
Clinical Lymphoma, Myeloma & Leukemia|June 22, 2013
Subcutaneous omacetaxine mepesuccinate in patients with chronic-phase chronic myeloid leukemia previously treated with 2 or more tyrosine kinase inhibitors including imatinibJorge E Cortes, Franck E Nicolini, Meir Wetzler, et al.
Oncotarget|September 23, 2016
A phase I-II trial of fludarabine, bendamustine and rituximab (FBR) in previously treated patients with CLLNitin Jain, Kumudha Balakrishnan, Alessandra Ferrajoli, et al.
The Pediatric Infectious Disease Journal|December 25, 2010
Sustained decline in rotavirus detections in the United States following the introduction of rotavirus vaccine in 2006Jacqueline E Tate, Jeffry D Mutuc, Catherine A Panozzo, et al.
American Journal of Hematology|June 5, 2015
Long-term efficacy and safety of bosutinib in patients with advanced leukemia following resistance/intolerance to imatinib and other tyrosine kinase inhibitorsCarlo Gambacorti-Passerini, Hagop M Kantarjian, Dong-Wook Kim, et al.
Blood|December 19, 2013
Bosutinib safety and management of toxicity in leukemia patients with resistance or intolerance to imatinib and other tyrosine kinase inhibitorsHagop M Kantarjian, Jorge E Cortes, Dong-Wook Kim, et al.
Brain Sciences|November 27, 2024
The Development of a Brief but Comprehensive Therapeutic Assessment Protocol for the Screening and Support of Youth in the Community to Address the Youth Mental Health CrisisMargaret Danielle Weiss, Eleanor Castine Richards, Danta Bien-Aime, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 29, 2008
Phase I study of alternate-week administration of tipifarnib in patients with myelodysplastic syndromeRazelle Kurzrock, Hagop M Kantarjian, Michelle A Blascovich, et al.
The Pediatric Infectious Disease Journal|December 25, 2010
Uptake, impact, and effectiveness of rotavirus vaccination in the United States: review of the first 3 years of postlicensure dataJacqueline E Tate, Margaret M Cortese, Daniel C Payne, et al.
British Journal of Haematology|November 6, 2015
Factors influencing long-term efficacy and tolerability of bosutinib in chronic phase chronic myeloid leukaemia resistant or intolerant to imatinibTim H Brümmendorf, Jorge E Cortes, Hanna J Khoury, et al.
Pageof 59